- Leukemia (AML): Bristol-Myers Squibb Onureg was approved by EU
- Diet can change intestinal and breast flora and affects breast cancer risk
- WHO: Delta variant will become the world main popular variant virus strain
- Clinical application of interleukin in tumor immunotherapy
- Red meats: DNA damage and colorectal cancer-related gene mutations
- Why reversing intravenous thrombolysis after DOAC is not recommended?
Nature Sub-Journal: Oxford-AstraZeneca adenovirus COVID-19 vaccine is related to bleeding diseases
Oxford-AstraZeneca COVID-19 vaccine is related to bleeding diseases. Since the COVID-19 pandemic, many scientific research institutions around the world have invested in the research and development of COVID-19 vaccines, and a record number of effective COVID-19 vaccines have been developed in just one year, which has played an important role in curbing the COVID-19 epidemic. effect.
With the large-scale vaccination of vaccines, a very small number of people began to have side effects. Among them, the adenovirus COVID-19 vaccine ChAdOx1 developed by Oxford-AstraZeneca was pushed to the forefront. As of March 31, 2021, 79 people were vaccinated first. Thrombosis occurred after the vaccine was administered, and 19 of them died. Is there a direct relationship between the vaccine and the thrombus? This has caused heated discussions, but it has been inconclusive.
On June 9, 2021, researchers from the University of Edinburgh and other units in the United Kingdom published a research paper titled: First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland in the top international medical journal Nature Medicine. .
The research team’s national survey of more than 2.5 million Scottish adults who had received the first dose of Oxford-AstraZeneca’s COVID-19 adenovirus vaccine (ChAdOx1) or Pfizer-BioNTech’s COVID-19 mRNA vaccine (BNT162b2) showed that Oxford-AstraZeneca The Likang vaccine is associated with a slightly increased risk of an autoimmune bleeding disorder called immune thrombocytopenic purpura (ITP).
The study also found that there may be evidence that the Oxford-AstraZeneca vaccine is associated with an increased risk of other bleeding and vascular problems. These small risks are important but rare, and are comparable to the risks of other vaccines, including vaccines for hepatitis B, cysticercosis, mumps, rubella, and influenza.
Clinical trials have shown that two vaccines against the new coronavirus, Oxford-AstraZeneca (ChAdOx1) and Pfizer-BioNTech (BNT162b2), are generally well tolerated, but there are a few reports of serious side effects.
After 22 million first injections and 6.8 million second injections, MHRA received 209 cases of thrombocytopenic purpura and thromboembolism (bleeding diseases and thromboembolism, respectively) Report.
In order to investigate the possibility that the COVID-19 vaccine is related to the progression of blood diseases, the research team investigated 2.53 million Scottish adults who received the first dose of the COVID-19 vaccine (the most common is ChAdOx1 or BNT162b2) between December 2020 and April 2021. People (57% of the adult population over the age of 18) have bleeding and vascular events related to the vaccine.
The authors found that in this population, ChAdOx1 vaccine is associated with a slight increase in the risk of immune thrombocytopenic purpura (ITP) for up to 27 days after injection. The disease causes slight bruising and excessive bleeding in some patients, and some patients Will suffer from chronic diseases. It is estimated that 1.13 cases occur out of every 100,000 injections of the first dose.
The analysis also showed that within 27 days of ChAdOx1 injection, there was a slight increase in the risk of other arterial thrombosis and bleeding events. However, there is insufficient evidence that ChAdOx1 is related to cerebral venous sinus thrombosis (a rare disease that forms a blood clot in the brain). The authors found no evidence that the BNT162b2 vaccine is associated with an increased risk of these adverse events.
The author emphasizes that the benefits of ChAdOx1 are very clear, and these findings should be understood in this context. The risk of serious adverse events caused by the vaccine is much lower than the risk of severe illness or death caused by new coronary pneumonia, especially for the elderly and other vulnerable groups. Further research needs to include younger people (because the vaccination plan determines the target population based on age and underlying diseases, there are relatively few people under 40 in this study) and evaluate the response to the second dose of vaccine.
(source:internet, reference only)